Clear Eyes Supply Disruption Weighs on Prestige Consumer Healthcare Inc. (PBH)’s Quarterly Revenue
Prestige Consumer Healthcare Inc. (PBH) reported a 2.4% year-over-year decline in fiscal third-quarter sales, primarily due to supply issues with its Clear Eyes brand. Despite this, sales of $283.4 million were roughly in line with company projections and slightly above Street estimates. Canaccord maintained a Buy rating on PBH but slightly reduced its price target to $86.
Clear Eyes Supply Disruption Weighs on Prestige Consumer Healthcare Inc. (PBH)'s Quarterly Revenue
Prestige Consumer Healthcare Inc. (PBH) reported a 2.4% year-over-year decline in fiscal third-quarter sales, primarily due to supply issues with its Clear Eyes brand. Despite this, sales of $283.4 million were in line with projections and slightly above Street estimates. The company reduced its fiscal 2026 sales outlook to $1.1 billion but maintained free cash flow projections of at least $245 million, while also completing an acquisition and share repurchases.
Insider Sell: Jeffrey Zerillo Sells 1,000 Shares of Prestige Con
Jeffrey Zerillo, Senior Vice President of Operations at Prestige Consumer Healthcare Inc's subsidiary, sold 1,000 shares of the company on February 11, 2026. Following this transaction, Zerillo now owns 41,048 shares. The stock is currently deemed fairly valued based on its GF Value, with a price-to-GF-Value ratio of 0.99.
Prestige Consumer Healthcare (NYSE:PBH) VP Sells $65,930.00 in Stock
Prestige Consumer Healthcare's VP, Jeffrey Zerillo, sold 1,000 shares of company stock worth $65,930 on February 11th, reducing his holding by 2.38%. This transaction follows previous sales in December and November. The company recently reported Q4 earnings of $1.14 per share, missing consensus estimates, and provided FY2026 EPS guidance of $4.54.
PBH's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Up
Prestige Consumer Healthcare Inc. (PBH) reported mixed results for its fiscal third quarter of 2026, with diluted EPS of $1.14 missing estimates but total revenues of $283.4 million surpassing expectations. The company's stock edged up 0.6% after the announcement. Despite beating revenue estimates, the company faced challenges with lower Eye & Ear Care category sales and narrowing operating margins, leading to a narrowed fiscal 2026 sales outlook.
PBH's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Up
Prestige Consumer Healthcare Inc. (PBH) reported third-quarter fiscal 2026 diluted earnings per share of $1.14, missing the Zacks Consensus Estimate, while total revenues of $283.4 million surpassed expectations despite a year-over-year dip. The company's stock rose 0.6% following the announcement. PBH also provided an updated fiscal 2026 outlook, narrowing its revenue and EPS guidance.
Prestige Consumer Healthcare Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Prestige Consumer Healthcare Inc. (NYSE:PBH) recently reported quarterly results where revenues matched forecasts, but statutory earnings per share fell 16% short of analyst expectations at US$0.97. Despite the earnings miss, analysts have largely maintained their financial forecasts and price targets for 2027, with anticipated revenues of US$1.13 billion and EPS of US$4.81. The company's revenue growth is expected to slow compared to historical performance and the wider industry, but analysts remain confident in their valuations.
How Mixed Q3 Results, Buybacks and Pillar5 Deal At Prestige (PBH) Have Changed Its Investment Story
Prestige Consumer Healthcare (PBH) reported mixed Q3 2026 results with lower sales and earnings and trimmed full-year revenue guidance to US$1.10 billion, alongside continued share repurchases and the Pillar5 acquisition aimed at addressing Clear Eyes supply constraints. The company emphasizes strong free cash flow and investment flexibility, but investors are watching whether supply chain improvements and capital management will impact its valuation, especially given a Simply Wall St fair value estimate of US$77 compared to market pricing. The article suggests investors consider multiple viewpoints and conduct their own research, highlighting potential undervaluation and the trade-off between buybacks and growth investment.
$1.1B sales target: Prestige tightens 2026 view as Clear Eyes supply drags
Prestige Consumer Healthcare (PBH) reported Q3 fiscal 2026 results with $283.4M revenue and $0.97 diluted EPS, narrowing its fiscal 2026 guidance to approximately $1.1B revenue and $4.54 adjusted diluted EPS. The company maintained free cash flow guidance at $245M+ despite a revenue decline primarily due to ongoing Clear Eyes supply constraints, which impacted Eye & Ear Care sales. PBH also completed the acquisition of Pillar5 Pharma and repurchased shares, emphasizing strong cash flow and capital allocation.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Rating of "Hold" from Analysts
Prestige Consumer Healthcare Inc. (NYSE:PBH) has received an average rating of "Hold" from analysts, with four rating it a hold and three a buy, and an average 12-month price target of $80.60. The company recently reported a slight Q3 EPS miss and revenue decline but narrowed its fiscal 2026 revenue outlook to $1.1 billion, citing improving supply for its Clear Eyes brand. Insider transactions show a VP selling shares, while institutional investors have adjusted their positions, with overall institutional ownership at approximately 99.95%.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Prestige Consumer Healthcare (PBH), McKesson (MCK) and Bristol-Myers Squibb (BMY)
Analysts have provided mixed ratings for several healthcare stocks. Prestige Consumer Healthcare (PBH) received a Buy rating from William Blair, with a "Strong Buy" consensus. McKesson (MCK) was maintained at a Buy rating by Evercore ISI and upgraded to Buy by TipRanks-OpenAI, also holding a "Strong Buy" consensus. Bristol-Myers Squibb (BMY) received a Hold rating from William Blair and Citi, resulting in a "Moderate Buy" consensus.
Prestige Consumer Healthcare: Fiscal Q3 Earnings Snapshot
Prestige Consumer Healthcare Inc. (PBH) reported fiscal third-quarter earnings of $46.7 million, or 97 cents per share, which adjusted to $1.14 per share, falling short of Wall Street expectations of $1.16 per share. The company's revenue was $283.4 million, exceeding forecasts. For the full year, Prestige Consumer Healthcare expects earnings of $4.54 per share and revenue of $1.1 billion.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q3 2026 Earnings Call Transcript
Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its Q3 2026 earnings, reporting adjusted EPS of $1.14 against expectations of $1.16, with sales of $283 million slightly exceeding forecasts. The company discussed challenges with Clear Eyes supply constraints, which are expected to improve sequentially, and the strategic acquisition of Pillar Five to enhance its eye care production capabilities. Despite a volatile consumer environment, PBH maintained its full-year free cash flow outlook of $245 million or more and affirmed its commitment to shareholder value through opportunistic share repurchases and potential M&A.
Prestige Consumer Healthcare (NYSE:PBH) Releases Earnings Results, Misses Expectations By $0.02 EPS
Prestige Consumer Healthcare (NYSE:PBH) reported adjusted EPS of $1.14, missing analyst estimates by $0.02, with revenue of $283.4 million, a 2.4% year-over-year decline. The company attributed the miss to Clear Eyes supply constraints and category softness in analgesics and cough & cold. Despite this, Prestige generated strong free cash flow and narrowed its FY2026 guidance, while shares traded down 3.3% following the announcement.
Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results
Prestige Consumer Healthcare Inc. reported its financial results for the third quarter and first nine months of fiscal 2026, exceeding revenue outlook despite a challenging consumer environment and lower Ear & Eye Care category sales due to supply limitations for Clear Eyes®. The company successfully closed the acquisition of Pillar5 Pharma, Inc., repurchased 0.8 million shares, and narrowed its fiscal 2026 revenue outlook to approximately $1.1 billion while maintaining a free cash flow outlook of $245 million or higher.
Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results
Prestige Consumer Healthcare Inc. reported its third quarter and year-to-date fiscal 2026 results, exceeding its revenue outlook with $283.4 million in Q3 and an adjusted diluted EPS of $1.14. Despite a challenging consumer environment and supply limitations for Clear Eyes®, the company successfully closed the acquisition of Pillar5 Pharma, Inc. and repurchased 0.8 million shares. Prestige is narrowing its fiscal 2026 revenue outlook to approximately $1.1 billion while maintaining a free cash flow outlook of $245 million or higher.
Prestige Looks Well Positioned for Durable Growth as Clear Eyes Issue Gradually Recovers
Morningstar analysts Keonhee Kim and Rashmi Nair believe Prestige Consumer Healthcare Inc. (PBH) is well-positioned for durable growth, citing the gradual recovery of their Clear Eyes product issue. The company's strategy focuses on product innovation, expanding household penetration, and increasing its e-commerce presence, particularly by broadening existing brands into adjacent, underpenetrated markets rather than competing with large CPG firms.
Prestige Consumer Healthcare (NYSE:PBH) Reports Mixed Q3 FY2026 Results, Misses Analyst Estimates
Prestige Consumer Healthcare (NYSE:PBH) reported mixed Q3 FY2026 results, with revenue slightly exceeding internal outlook but missing Wall Street forecasts, and adjusted EPS falling short of analyst estimates. The market reacted negatively, pushing the stock down over 5% in pre-market trading. The company's performance was impacted by supply chain constraints affecting its Clear Eyes® products, leading to a revenue decline, though strategic acquisition of Pillar5 Pharma, Inc. is expected to address these issues long-term.
Prestige Consumer Healthcare Q3 Earnings Miss Expectations
Prestige Consumer Healthcare reported Q3 non-GAAP EPS of $1.14, missing expectations by $0.02, and revenue of $283.4 million, down 2.4% year-over-year. The company revised its FY26 revenue outlook downwards to between $1.1 billion and $1.115 billion, anticipating an organic revenue decline of about 3%. Despite these challenges, Prestige Consumer Healthcare expects stable free cash flow of $245 million or more.
Prestige Consumer Healthcare: Fiscal Third Quarter Earnings Overview
Prestige Consumer Healthcare reported its fiscal third-quarter results, with a net profit of $46.7 million and adjusted earnings of $1.14 per share, slightly below analyst expectations. The company's revenue reached $283.4 million, exceeding forecasts. For the full year, Prestige Consumer Healthcare anticipates annual earnings of $4.54 per share and total revenue of $1.1 billion.
Prestige Consumer Healthcare Inc. SEC 10-Q Report
Prestige Consumer Healthcare Inc. has released its Form 10-Q report for the third quarter of fiscal year 2025, detailing a decrease in total revenues by 2.4% to $283.4 million and a net income reduction to $46.7 million from $61.0 million year-over-year. The financial downturn was largely due to decreased sales in Eye & Ear Care and Analgesics, supply chain disruptions, and increased general and administrative expenses. To address these challenges, the company completed the acquisition of Pillar5 Pharma, Inc. to boost production capabilities, particularly for its Clear Eyes product line, while anticipating continued economic uncertainty.
Prestige Consumer Healthcare: Fiscal Q3 Earnings Snapshot
Prestige Consumer Healthcare Inc. (PBH) reported fiscal third-quarter earnings of $46.7 million, or 97 cents per share. Adjusted earnings of $1.14 per share fell short of analyst expectations, though revenue of $283.4 million surpassed forecasts. The company expects full-year earnings of $4.54 per share and revenue of $1.1 billion.
Prestige Consumer Healthcare Inc. Reports Retreat In Q3 Income
Prestige Consumer Healthcare Inc. reported a decline in its third-quarter earnings. The company's earnings dropped to $46.69 million, or $0.97 per share, compared to $61.03 million, or $1.22 per share, in the same period last year. Revenue also decreased by 2.4% to $283.44 million.
Prestige Consumer Healthcare Inc. (PBH): A Bull Case Theory
This article summarizes a bull thesis on Prestige Consumer Healthcare Inc. (PBH), highlighting its recent acquisition of Stampede Culinary Partners for $662.5 million, which is expected to significantly boost EBITDA and EPS. Despite recent choppy performance, PBH's earnings have grown considerably since 2017 while its stock trades near mid-2017 levels, suggesting an attractive valuation with strong growth potential through strategic acquisitions and organic expansion. The company offers an attractive risk/reward opportunity, especially if it successfully integrates Stampede and realizes operational efficiencies.
Jefferies Maintains Hold on Prestige Consumer Healthcare Inc. (PBH) Jan 30 2026
Jefferies maintained a "Hold" rating on Prestige Consumer Healthcare Inc. (PBH) on January 30, 2026, while lowering its price target from $70 to $66. This adjustment reflects concerns about company fundamentals and near-term margin pressure, suggesting limited immediate upside for the stock. Meyka AI gives PBH a B+ grade, balancing its steady cash flow prospects with current headwinds.
Great Lakes Advisors LLC Has $4.96 Million Stake in Prestige Consumer Healthcare Inc. $PBH
Great Lakes Advisors LLC reduced its stake in Prestige Consumer Healthcare Inc. by 33.9% in Q3, now owning 79,435 shares valued at $4.96 million, representing 0.16% of the company. Institutional investors hold nearly 99.95% of the stock. Analysts currently maintain a "Moderate Buy" consensus rating with an average target price of $84.50, despite some recent price target adjustments.
Prestige Consumer Healthcare (PBH) Expected to Announce Quarterly Earnings on Thursday
Prestige Consumer Healthcare (PBH) is projected to release its Q3 2026 earnings on Thursday, February 5th, with analysts expecting $1.16 EPS and $286.93 million in revenue. The company previously surpassed estimates in the last quarter, reporting $1.07 EPS. Wall Street analysts currently rate PBH as a "Moderate Buy" with an average target price of $85.33.
Y Intercept Hong Kong Ltd Has $2.04 Million Stock Position in Prestige Consumer Healthcare Inc. $PBH
Y Intercept Hong Kong Ltd significantly increased its stake in Prestige Consumer Healthcare (NYSE: PBH) by 899.2% in Q3, now holding 32,635 shares valued at $2.04 million. Prestige Consumer Healthcare exceeded Q3 expectations with an EPS of $1.07 and revenue of $274.1 million, despite a slight year-over-year revenue decrease. The company has a "Moderate Buy" consensus rating from analysts, with an average price target of $85.33, while institutional investors own nearly all of the stock.
(PBH) Price Dynamics and Execution-Aware Positioning
This article provides an AI-driven analysis of Prestige Consumer Healthcare Inc. (NYSE: PBH), highlighting strong near and mid-term sentiment but a weak long-term outlook with elevated downside risk. It details multiple institutional trading strategies including long, breakout, and short positions, each with specific entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis, identifying support and resistance levels for various periods.
Massachusetts Financial Services Co. MA Sells 42,171 Shares of Prestige Consumer Healthcare Inc. $PBH
Massachusetts Financial Services Co. MA reduced its holdings in Prestige Consumer Healthcare Inc. by 6.7% in Q3, selling 42,171 shares and now owning 590,297 shares valued at approximately $36.8 million. Prestige Consumer Healthcare exceeded earnings expectations, reporting $1.07 EPS against an anticipated $0.97, and provided FY2026 guidance of $4.540-$4.580 EPS. Analyst sentiment is generally positive, with a "Moderate Buy" average rating and an average price target of $85.33 for the stock.
Analysts Are Bullish on Top Healthcare Stocks: Prestige Consumer Healthcare (PBH), Boston Scientific (BSX)
This article highlights bullish analyst sentiments on three healthcare stocks: Prestige Consumer Healthcare (PBH), Boston Scientific (BSX), and Gilead Sciences (GILD). Analysts from William Blair and Truist Financial maintained "Buy" ratings for these companies, citing strong performance and significant upside potential based on average price targets. The report details specific analyst ratings, price targets, and success rates for each stock.
Analysts Are Bullish on Top Healthcare Stocks: Prestige Consumer Healthcare (PBH), Boston Scientific (BSX)
Analysts are bullish on several healthcare stocks, including Prestige Consumer Healthcare (PBH), Boston Scientific (BSX), and Gilead Sciences (GILD). William Blair maintained a Buy rating on Prestige Consumer Healthcare, while Truist Financial analysts reinforced Buy ratings on both Boston Scientific and Gilead Sciences, citing strong consensus ratings and upside potential for all three companies.
Analysts Are Bullish on Top Healthcare Stocks: Prestige Consumer Healthcare (PBH), Boston Scientific (BSX)
Analysts are expressing bullish sentiments on several healthcare stocks, including Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). William Blair maintained a Buy rating on PBH with a $77.00 average price target, while Truist Financial and Bank of America Securities maintained Buy ratings on BSX, with analysts projecting a 32.2% upside. Gilead Sciences (GILD) also received a Strong Buy consensus, with analysts at Truist Financial and Scotiabank maintaining Buy ratings.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Rating of "Moderate Buy" from Brokerages
Prestige Consumer Healthcare (NYSE:PBH) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $85.33. The company recently reported strong quarterly earnings, beating analyst expectations for EPS and revenue, and provided FY2026 EPS guidance largely in line with forecasts. Institutional investors hold a significant majority of the stock, while insider selling has been minimal.
(PBH) as a Liquidity Pulse for Institutional Tactics
This article provides an AI-driven analysis of Prestige Consumer Healthcare Inc. (PBH), highlighting a positive near-term sentiment but broader weak alignment and elevated downside risk. It offers three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis to guide investors. The analysis includes support and resistance levels across different time horizons, emphasizing the use of AI models for optimized trading decisions.
Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference
Prestige Consumer Healthcare Inc. (NYSE: PBH) will release its fiscal 2026 third-quarter earnings on Thursday, February 5, 2026, followed by a conference call at 8:30 a.m. ET. The company will also participate in a fireside chat at the 28th Annual ICR Conference on Tuesday, January 13, 2026, at 9:30 a.m. ET. Both events will have live audio webcasts accessible from the Investor Relations page of their website.
Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference
Prestige Consumer Healthcare Inc. (NYSE: PBH) will release its fiscal 2026 third-quarter earnings on Thursday, February 5, 2026, followed by a conference call that same morning. The company also confirmed its participation in the 28th Annual ICR Conference on Tuesday, January 13, 2026, where it will host a fireside chat. Both events will have live audio webcasts available on the company's Investor Relations page.
Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference
Prestige Consumer Healthcare Inc. will release its fiscal 2026 third-quarter earnings on February 5, 2026, followed by a conference call at 8:30 a.m. ET. The company will also participate in a fireside chat at the 28th Annual ICR Conference on January 13, 2026, at 9:30 a.m. ET. Both events will have live webcasts accessible through the company's Investor Relations page.
Health products company sets dates to share its latest results
Prestige Consumer Healthcare (NYSE: PBH) announced it will release its fiscal 2026 third-quarter earnings on Thursday, February 5, 2026, before market open, followed by a conference call at 8:30 a.m. ET. The company will also participate in a fireside chat at the 28th Annual ICR Conference on Tuesday, January 13, 2026, at 9:30 a.m. ET. Historically, scheduling announcements have led to modest market reactions, while actual earnings reports have driven larger movements.
We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Prestige Consumer Healthcare (NYSE:PBH) has a manageable debt load, with net debt of US$874.0m as of September 2025. The company's debt-to-EBITDA ratio of 2.3 and strong interest coverage (EBIT 8.1 times interest expense) indicate responsible debt management. While liabilities currently outweigh cash and near-term receivables, the company's valuation of US$3.02b suggests it could raise capital if needed, and its free cash flow covers 71% of EBIT, allowing for debt reduction.
Prestige Consumer Healthcare (PBH) upgraded to buy: Here's what you should know
This article announces that Prestige Consumer Healthcare (PBH) has received an upgraded "buy" rating. It suggests that investors should take note of this development, implying a potentially positive outlook for the company's stock.
Is This the Right Time to Add PBH Stock to Your Portfolio?
Prestige Consumer Healthcare (PBH) shows strong momentum in e-commerce and a stable financial position, aided by strategic acquisitions like Pillar5 Pharma Inc. However, the company faces macroeconomic headwinds such as inflation and tariff costs. Despite these challenges, PBH has a positive earnings outlook and Zacks #2 (Buy) Rank, suggesting it might be a good addition to an investment portfolio.
Is This the Right Time to Add PBH Stock to Your Portfolio?
Prestige Consumer Healthcare (PBH) shows strong e-commerce momentum, and growth through acquisitions like Pillar5 Pharma Inc., and stable solvency, making it a "Buy" rated stock. Despite an anticipated decline in fiscal 2026 revenues and cost headwinds from inflation and tariffs, the company is implementing cost-saving initiatives and tactical pricing. Its consistent profitability and digital marketing investments position it for continued success.
Allspring Global Investments Holdings LLC Buys 70,376 Shares of Prestige Consumer Healthcare Inc. $PBH
Allspring Global Investments Holdings LLC significantly increased its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 4.6% in the third quarter, now owning 1,592,375 shares valued at approximately $100.9 million. This investment firm now holds about 3.24% of the company. Prestige Consumer Healthcare exceeded Q3 earnings expectations, reporting $1.07 EPS against $0.97 expected and $274.1 million in revenue, while providing a positive FY2026 EPS guidance of $4.54–$4.58.
Prestige Consumer Healthcare Inc. $PBH Stock Holdings Trimmed by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC reduced its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 5.6% during the third quarter, selling 30,225 shares. The fund now holds 509,668 shares valued at $31.8 million, making PBH its 12th largest holding. Prestige Consumer Healthcare exceeded Q3 EPS estimates and reported $274.1 million in revenue, while institutional investors own 99.95% of the stock.
Zacks Research Has Bullish Forecast for PBH Q1 Earnings
Zacks Research has issued a bullish forecast for Prestige Consumer Healthcare (NYSE:PBH) Q1 2027 earnings, raising their EPS estimate to $1.24 and maintaining a "Hold" rating. This update comes after Prestige Consumer Healthcare surpassed Q4 expectations with $1.07 EPS and $274.11M in revenue, and set an optimistic FY2026 guidance. Analyst sentiment remains mixed, leading to a "Moderate Buy" consensus.
Assenagon Asset Management S.A. Takes Position in Prestige Consumer Healthcare Inc. $PBH
Assenagon Asset Management S.A. initiated a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) during Q3, acquiring 30,286 shares valued at approximately $1.89 million, making it one of several institutions to recently adjust their holdings. The company reported strong Q3 earnings, beating EPS and revenue estimates, and provided positive FY2026 guidance. Despite some recent analyst price target adjustments and a minor insider stock sale, institutional investors hold a significant 99.95% of the stock, with a consensus "Moderate Buy" rating and an average price target of $85.33.
Congress Asset Management Co. Trims Stock Holdings in Prestige Consumer Healthcare Inc. $PBH
Congress Asset Management Co. significantly cut its stake in Prestige Consumer Healthcare Inc. by 70.7% in Q3 2025, selling 714,172 shares and retaining 295,423 shares valued at approximately $18.43 million. Despite this, Prestige Consumer Healthcare surpassed its Q3 earnings and revenue estimates, and analysts maintain a "Moderate Buy" consensus rating with a target price significantly above the current stock price. Other institutional investors, however, increased their holdings in the company during the same period.
Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Consensus Rating of "Moderate Buy" by Brokerages
Prestige Consumer Healthcare Inc. (NYSE:PBH) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 1-year price target of $85.33. The company recently reported strong earnings, beating EPS and revenue estimates, and provided positive FY2026 guidance. Insider activity includes a sale by VP Jeffrey Zerillo, while institutional investors hold nearly all of the company's stock.
What Prestige Consumer Healthcare (PBH)'s Buybacks and Brandes Stake Mean for Cash-Flow-Focused Shareholders
Prestige Consumer Healthcare (PBH) recently saw a new stake from Brandes Small Cap Value Fund and confirmed share repurchases of about 4.7% since mid-2024. These actions, alongside fiscal 2026 revenue guidance indicating modest organic decline, suggest growing confidence in the company's acquisition-led model and its focus on resilient OTC brands. The article explores how these developments impact PBH's cash-flow-driven investment narrative, noting that the Simply Wall St Community currently values PBH at US$78, a 26% upside to its current price.
